JS Link

JS Link Equity

The The Equity of JS Link (127120.KQ) as of Oct 26, 2026 is 68.59 B KRW. In the previous year, The Equity was 25.03 B KRW — a change of 174.05% (higher).

Equity

68.59 BKRW

YoY

174.05%

Last updated:

In 2025, JS Link's equity was 68.59 B KRW, a 174.05% increase from the 25.03 B KRW equity in the previous year.

The JS Link Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
19.60 B KRW
Jan 1, 2019
9.66 B KRW
Jan 1, 2020
38.70 B KRW
Jan 1, 2021
32.77 B KRW
Jan 1, 2022
27.89 B KRW
Jan 1, 2023
26.28 B KRW
Jan 1, 2024
25.03 B KRW
Jan 1, 2025
68.59 B KRW
The JS Link Equity history
YEAREquityYoY
68.59 BKRW+174.05%
25.03 BKRW-4.75%
26.28 BKRW-5.78%
27.89 BKRW-14.89%
32.77 BKRW-15.33%
38.70 BKRW+300.56%
9.66 BKRW-50.71%
19.60 BKRW-17.13%
23.66 BKRW+1,203.01%
1.82 BKRW-83.79%
11.20 BKRW+44.87%
7.73 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Equity Details

Analyzing JS Link's Equity

JS Link's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding JS Link's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating JS Link's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

JS Link's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in JS Link’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about JS Link stock

The Equity of JS Link is 68.59 B KRW in 2025.

The Equity of JS Link changed from 25.03 B KRW to 68.59 B KRW, representing a 174.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity JS Link since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's JS Link historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JS Link

All Key Metrics — JS Link